LLY

1,011.28

-2.39%↓

JNJ

202.37

-1.51%↓

ABBV

228.23

-0.06%↓

UNH

334.44

-0.4%↓

AZN

90.21

-0.67%↓

LLY

1,011.28

-2.39%↓

JNJ

202.37

-1.51%↓

ABBV

228.23

-0.06%↓

UNH

334.44

-0.4%↓

AZN

90.21

-0.67%↓

LLY

1,011.28

-2.39%↓

JNJ

202.37

-1.51%↓

ABBV

228.23

-0.06%↓

UNH

334.44

-0.4%↓

AZN

90.21

-0.67%↓

LLY

1,011.28

-2.39%↓

JNJ

202.37

-1.51%↓

ABBV

228.23

-0.06%↓

UNH

334.44

-0.4%↓

AZN

90.21

-0.67%↓

LLY

1,011.28

-2.39%↓

JNJ

202.37

-1.51%↓

ABBV

228.23

-0.06%↓

UNH

334.44

-0.4%↓

AZN

90.21

-0.67%↓

Search

Simulations Plus Inc

Ouvert

SecteurSoins de santé

20.68 3.82

Résumé

Variation du prix de l'action

24h

Actuel

Min

19.83

Max

20.74

Chiffres clés

By Trading Economics

Revenu

-70M

-67M

Ventes

-2.1M

20M

P/E

Moyenne du Secteur

48.528

80.03

Rendement du dividende

0.48

Marge bénéficiaire

-330.585

Employés

243

EBITDA

327K

5.3M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+0.74% upside

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

0.48%

2.29%

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-7M

344M

Ouverture précédente

16.86

Clôture précédente

20.68

Sentiment de l'Actualité

By Acuity

56%

44%

310 / 374 Classement par Healthcare

Simulations Plus Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

3 déc. 2025, 23:21 UTC

Résultats
Acquisitions, Fusions, Rachats

EQB to Buy Loblaw Unit PC Financial for About $573.5 Million -- Update

3 déc. 2025, 23:14 UTC

Acquisitions, Fusions, Rachats

EQB to Buy PC Financial From Loblaw for About $573.5 Million

3 déc. 2025, 22:01 UTC

Principaux Mouvements du Marché

Costco Wholesale Reports Higher Monthly Sales

3 déc. 2025, 21:38 UTC

Résultats

Salesforce Raises Revenue Forecast as Agentforce Sales Top $500 Million

3 déc. 2025, 23:59 UTC

Market Talk

Australian Coal Prices Seen Having Recovered Well -- Market Talk

3 déc. 2025, 23:49 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

3 déc. 2025, 23:49 UTC

Market Talk

HSBC Chair Appointment Unlikely to Have Material Operational Impact -- Market Talk

3 déc. 2025, 23:49 UTC

Market Talk

Nikkei May Decline Amid Caution Over U.S. Labor Market -- Market Talk

3 déc. 2025, 23:13 UTC

Market Talk

Australian Treasurer Says Economy Not On Drip of Govt Spending -- Market Talk

3 déc. 2025, 23:10 UTC

Résultats

Salesforce Raises Forecast as Agentforce Sales Top $500M -- Update

3 déc. 2025, 23:08 UTC

Market Talk

Goodman's New Bull Sees Profit Upgrade on Cards -- Market Talk

3 déc. 2025, 23:06 UTC

Acquisitions, Fusions, Rachats

EQB to Buy Loblaw Unit PC Financial for About $573.5M -- Update

3 déc. 2025, 22:59 UTC

Acquisitions, Fusions, Rachats

EQB to Buy PC Financial From Loblaw for About $573.5M

3 déc. 2025, 22:45 UTC

Market Talk

WiseTech Investor Day Increases Bull's Confidence -- Market Talk

3 déc. 2025, 22:20 UTC

Résultats

Salesforce CEO: 9,500 of 18,500 Total Closed Agentforce Deals Are Paid

3 déc. 2025, 22:19 UTC

Résultats

Salesforce CEO: Six Out of 10 Biggest Deals in 3Q Came from Agentforce

3 déc. 2025, 22:17 UTC

Résultats

Salesforce Working to Add Voice to Agentforce, CEO Says

3 déc. 2025, 22:16 UTC

Résultats

Salesforce CEO: Williams-Sonoma's Agentforce Makes Up 60% of Customer Chats

3 déc. 2025, 22:15 UTC

Résultats

Salesforce CEO: Agentforce ARR Was $540M in 3Q

3 déc. 2025, 22:10 UTC

Acquisitions, Fusions, Rachats

EQB: Will Enter Into a Long-Term Strategic Relationship With Loblaw >EQB.T

3 déc. 2025, 22:09 UTC

Acquisitions, Fusions, Rachats

EQB: Agreed to Acquire PC Fincl From Loblaw >EQB.T

3 déc. 2025, 21:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

3 déc. 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

3 déc. 2025, 21:49 UTC

Résultats

Salesforce Reports Mounting Profits. The Stock Is Rising. -- Barrons.com

3 déc. 2025, 21:23 UTC

Résultats

Salesforce Raises Revenue Forecast as Agentforce Sales Top $500M

3 déc. 2025, 21:19 UTC

Résultats

Salesforce Reports Mounting Profits. The Stock Is Rising. -- Barrons.com

3 déc. 2025, 21:06 UTC

Résultats

Salesforce Reports Mixed Earnings. The Stock Is Rising. -- Barrons.com

3 déc. 2025, 21:04 UTC

Résultats

Salesforce Sees Profitable Growth Framework Target of 50 by FY30 >CRM

3 déc. 2025, 21:04 UTC

Résultats

Salesforce Targets $60 B Plus Organic Rev by FY30 >CRM

3 déc. 2025, 21:03 UTC

Résultats

Salesforce Raises FY26 Oper Cash Flow Growth Guidance to 13% to 14% Y/Y >CRM

Comparaison

Variation de prix

Simulations Plus Inc prévision

Objectif de Prix

By TipRanks

0.74% hausse

Prévisions sur 12 Mois

Moyen 20.5 USD  0.74%

Haut 25 USD

Bas 16 USD

Basé sur 5 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

5 ratings

3

Achat

2

Maintien

0

Vente

Sentiment

By Acuity

310 / 374Classement par Soins de santé

Sentiment de l'Actualité

Indications Baissières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Supérieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
help-icon Live chat